How far have AAV platforms taken us? Lessons from a CDMO on accelerating time-to-clinic

Time to clinic remains a critical success factor for both emerging biotech’s and established pharmaceutical organisations in the cell and gene therapy (CGT) sector. Driven by competitive pressures and milestone-based funding models, alongside a commitment to deliver life-changing treatments to patients in need, the urgency to advance novel therapies into the clinic has never been greater. In response, a range of adeno-associated virus (AAV) platform technologies have emerged, each aiming to streamline development and reduce timelines. This article explores how far platform-based approaches can go in accelerating time to clinic. Drawing on real-world insights from a contract development and manufacturing organisation (CDMO), we examine key process and technology innovations, the pivotal role of analytics in expediting development, and the future evolution of AAV platforms.